PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

January 19, 2024

Study Completion Date

January 19, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

PF-06863135 monotherapy IV or SC

PF-06863135 will be administered intravenously or subcutaneously.

DRUG

PF-06863135 + dexamethasone

PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.

DRUG

PF-06863135 + lenalidomide

PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally

DRUG

PF-06863135 + pomalidomide

PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally

Trial Locations (37)

10021

Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Cancer Center at Westchester, Harrison

11553

Memorial Sloan Kettering Cancer Center at Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center at Commack, Commack

27705

Duke University Health System: Adult Bone Marrow Transplant Clinic, Durham

27710

Duke Cancer Center, Durham

Duke University Hospital, Durham

30342

Blood and Marrow Transplant Group of Georgia, Atlanta

Northside Hospital, Atlanta

37232

Henry Joyce Cancer Center, Nashville

52242

University of Iowa Hospitals and Clinics, Iowa City

60422

UChicago Medicine at Ingalls - Flossmoor, Flossmoor

60426

UChicago Medicine Ingalls Memorial, Harvey

60451

University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox

60462

The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park

60477

UChicago Medicine at Ingalls - Tinley Park, Tinley Park

60611

UChicago Medicine - River East, Chicago

60637

The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy, Chicago

University of Chicago Medical Center, Chicago

70121

Ochsner Clinic Foundation, New Orleans

75246

Baylor University Medical Center, Dallas

Investigational Drug Services, Baylor University Medical Center, Dallas

92024

UCSD Medical Center - Encinitas, Encinitas

92037

UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital), La Jolla

UC San Diego Moores Cancer Center, La Jolla

92081

UCSD Medical Center - Vista, Vista

92103

UC San Diego Medical Center - Hillcrest, San Diego

02114

Massachusetts General Hospital, Boston

07920

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Cancer Center at Monmouth, Middletown

07645

Memorial Sloan Kettering Cancer Center at Bergen, Montvale

T2N 2T9

Unit 57, Special Services Building, Calgary

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

M5G2M9

University Health Network - Princess Margaret Cancer Centre, Toronto

H4A3J1

MUHC, GLEN site, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT03269136 - PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter